Real-world adherence, persistence, and in-class switching during use of dipeptidyl peptidase-4 inhibitors: a systematic review and meta-analysis involving 594,138 patients with type 2 diabetes.

Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9200299 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-5233 (Electronic) Linking ISSN: 09405429 NLM ISO Abbreviation: Acta Diabetol Subsets: MEDLINE

Publication: Berlin : Springer Verlag
Original Publication: Berlin : Springer International, c1991-

Diabetes Mellitus, Type 2/*drug therapy ; Diabetes Mellitus, Type 2/*epidemiology ; Dipeptidyl-Peptidase IV Inhibitors/*therapeutic use ; Drug Substitution/*statistics & numerical data ; Medication Adherence/*statistics & numerical data; Adolescent ; Adult ; Aged ; Aged, 80 and over ; Cohort Studies ; Female ; Humans ; Hypoglycemic Agents/therapeutic use ; Male ; Middle Aged ; Treatment Outcome ; Withholding Treatment/statistics & numerical data ; Young Adult

Aims: Medication adherence and persistence are important determinants of treatment success in type 2 diabetes mellitus (T2DM). This systematic review and meta-analysis evaluated the real-world adherence, persistence, and in-class switching among patients with T2DM prescribed dipeptidyl peptidase-4 (DPP4) inhibitors.
Methods: MEDLINE, EMBASE, Cochrane Library, PsychINFO, and CINAHL were searched for relevant observational studies published in the English language up to 20 December 2019. This was supplemented by manual screening of the references of included papers. Random-effects meta-analysis was performed.
Results: Thirty-four cohort studies involving 594,138 patients with T2DM prescribed DPP4 inhibitors from ten countries were included. The pooled proportion adherent (proportion of days covered (PDC) or medication possession ratio (MPR) ≥ 0.80) was 56.9% (95% confidence interval [CI] 49.3-64.4) at one year and 44.2% (95% CI 36.4-52.1) at two years. The proportion persistent with treatment decreased from 75.6% (95% CI 71.5-79.5) at six months to 52.8% (95% CI 51.6-59.8) at two years. No significant differences in adherence and persistence were observed between individual DPP4 inhibitors. At one year, just 3.2% (95% CI 3.1-3.3) of patients switched from one DPP4 inhibitor to another. Switching from saxagliptin and alogliptin to others was commonest.
Conclusions: Adherence to and persistence with DPP4 inhibitors is suboptimal but similar across all medications within the class. While in-class switching is uncommon, saxagliptin and alogliptin are the DPP4 inhibitors most commonly switched. Interventions to improve treatment adherence and persistence among patients with T2DM prescribed DPP4 inhibitors may be warranted.

Davies MJ, D'Alessio DA, Fradkin J et al (2018) A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018(41):2669–2701. (PMID: 10.2337/dci18-0033)
Buse JB, Wexler DJ, Tsapas A, et al. (2019) update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2020 Feb;63(2):221–228.
Deacon CF (2018) A review of dipeptidyl peptidase-4 inhibitors. Hot topics from randomized controlled trials. Diabetes Obes Metab 20(Suppl 1):34–46. (PMID: 10.1111/dom.13135)
Raval AD, Vyas A (2020) National trends in diabetes medication use in the United States: 2008 to 2015. J Pharm Pract 33(4):433–442. (PMID: 10.1177/0897190018815048)
Dennis JM, Henley WE, McGovern AP et al (2019) Time trends in prescribing of type 2 diabetes drugs, glycaemic response and risk factors: a retrospective analysis of primary care data, 2010–2017. Diabetes Obes Metab 21:1576–1584. (PMID: 10.1111/dom.13687)
Cramer JA, Roy A, Burrell A et al (2008) Medication compliance and persistence: terminology and definitions. Value Health 11:44–47. (PMID: 10.1111/j.1524-4733.2007.00213.x)
Suzuki Y, Tanaka A, Tanak M et al (2019 Sep) Clinical effectiveness of switching between DPP-4 inhibitors in patients with type 2 diabetes mellitus. Int J Clin Pharmacol Ther 57(9):474–477. (PMID: 10.5414/CP203409)
Tanaka M, Nishimura T, Sekioka R, Itoh H (2016) Dipeptidyl peptidase-4 inhibitor switching as an alternative add-on therapy to current strategies recommended by guidelines: analysis of a retrospective cohort of type 2 diabetic patients. J Diabetes Metab 7:701. https://doi.org/10.4172/2155-6156.1000701. (PMID: 10.4172/2155-6156.1000701)
Strain WD, McEwan P, Howitt H et al (2019 Aug) Retrospective database analysis evaluating the clinical outcomes of changing treatment of people with type 2 diabetes mellitus (T2DM) from other DPP-4 inhibitor therapy to alogliptin in a primary care setting. Diabetes Ther 10(4):1499–1507. (PMID: 10.1007/s13300-019-0662-y)
Munir KM, Lamos EM (2017) Diabetes type 2 management: what are the differences between DPP-4 inhibitors and how do you choose? Expert Opin Pharmacother 18(9):839–841. (PMID: 10.1080/14656566.2017.1323878)
Canadian Agency for Drugs and Technologies in Health. Nesina Common Drug Review Pharmacoeconomic Review Report. Avialable at https://www.cadth.ca/sites/default/files/cdr/pharmacoeconomic/SR0368_Nesina_PE_Report.pdf (Accessed July 20 2020).
Moher D, Liberati A, Tetzlaff J et al (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097. (PMID: 10.1371/journal.pmed.1000097)
Pharmacy Quality Alliance. Adherence. Available at https://www.pqaalliance.org/resources/adherence.asp (Accessed January 12 2020).
Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from https://www.training.cochrane.org/handbook.
Balkau B, Charbonnel B, Penfornis A et al (2017) The use of saxagliptin in people with type 2 diabetes in France: the diapazon epidemiological study. Diabetes Ther 8:1147–1162. (PMID: 10.1007/s13300-017-0311-2)
Simon D, Detournay B, Eschwege E et al (2014) Use of vildagliptin in management of type 2 diabetes: effectiveness, treatment persistence and safety from the 2-year real-life VILDA study. Diabetes Ther 5:207–224. (PMID: 10.1007/s13300-014-0064-0)
McGovern AP, Dennis JM, Shields BM et al (2019 Apr 12) What to do with diabetes therapies when HbA1c lowering is inadequate: add, switch, or continue? A MASTERMIND study. BMC Med 17(1):79. (PMID: 10.1186/s12916-019-1307-8)
Karagiannis T, Paschos P, Paletas K et al (2012) Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ 344:e1369. (PMID: 10.1136/bmj.e1369)
Pinto LC, Rados DV, Barkan SS et al (2018) Dipeptidyl peptidase-4 inhibitors, pancreatic cancer and acute pancreatitis: a meta-analysis with trial sequential analysis. Sci Rep 8:782. (PMID: 10.1038/s41598-017-19055-6)
Scirica BM, Bhatt DL, Braunwald E et al (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369:1317–1326. (PMID: 10.1056/NEJMoa1307684)
Rosenstock J, Kahn SE, Johansen OE et al (2019) Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. JAMA 322:1155–1166. (PMID: 10.1001/jama.2019.13772)
Asche C, LaFleur J, Conner C (2011) A review of diabetes treatment adherence and the association with clinical and economic outcomes. Clin Ther 33:74–109. (PMID: 10.1016/j.clinthera.2011.01.019)
Kennedy-Martin T, Boye KS, Peng X (2017) Cost of medication adherence and persistence in type 2 diabetes mellitus: a literature review. Patient Prefer Adherence 11:1103–1117. (PMID: 10.2147/PPA.S136639)
Carls GS, Tuttle E, Tan RD et al (2017) Understanding the gap between efficacy in randomized controlled trials and effectiveness in real-world use of GLP-1 RA and DPP-4 therapies in patients with type 2 diabetes. Diabetes Care 40:1469–1478. (PMID: 10.2337/dc16-2725)
Lindenmeyer A, Hearnshaw H, Vermeire E, Van Royen P, Wens J, Biot Y (2006) Interventions to improve adherence to medication in people with type 2 diabetes mellitus: a review of the literature on the role of pharmacists. J Clin Pharm Ther 31(5):409–419. (PMID: 10.1111/j.1365-2710.2006.00759.x)
Schoenthaler A, Cuffee Y (2013) A systematic review of interventions to improve adherence to diabetes medications within the patient-practitioner interaction. J Clin Outcomes Manage 20(11):494–506.
Vervloet M, van Dijk L, de Bakker DH et al (2014) Short- and long-term effects of real-time medication monitoring with short message service (SMS) reminders for missed doses on the refill adherence of people with type 2 diabetes: evidence from a randomized controlled trial. Diabet Med 31(7):821–828. (PMID: 10.1111/dme.12439)
Gourzoulidis G, Kourlaba G, Stafylas P et al (2017) Association between copayment, medication adherence and outcomes in the management of patients with diabetes and heart failure. Health Policy 121:363–377. (PMID: 10.1016/j.healthpol.2017.02.008)
Dolinar R, Kohn CG, Lavernia F, Nguyen E (2019) The non-medical switching of prescription medications. Postgrad Med 131(5):335–341. (PMID: 10.1080/00325481.2019.1618195)
McGovern A, Tippu Z, Hinton W et al (2018) Comparison of medication adherence and persistence in type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 20:1040–1043. (PMID: 10.1111/dom.13160)
Ofori-Asenso R, Sahle B, Chin KL et al (2020) Poor adherence and persistence to sodium glucose co-transporter 2 inhibitors in real world settings: evidence from a systematic review and meta-analysis. Diabetes Metab Res Rev 24:e3350. https://doi.org/10.1002/dmrr.3350. (PMID: 10.1002/dmrr.3350)
Jermendy G, Kiss Z, Rokszin R et al (2018) Persistence to treatment with novel antidiabetic drugs (dipeptidyl peptidase-4 inhibitors, sodium-glucose co-transporter-2 inhibitors, and glucagon-like peptide-1 receptor agonists) in people with type 2 diabetes: a nationwide cohort study. Diabetes Ther 9(5):2133–2141. (PMID: 10.1007/s13300-018-0483-4)

Keywords: Adherence; DPP4 inhibitors; Dipeptidyl peptidase-4 inhibitors; Discontinuation; Gliptins; Hypoglycemic agents; Persistence; Switching

0 (Dipeptidyl-Peptidase IV Inhibitors)
0 (Hypoglycemic Agents)

Date Created: 20200819 Date Completed: 20210305 Latest Revision: 20210305

20231215

10.1007/s00592-020-01590-w

32809070